Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma
Isocitrate dehydrogenase (IDH) is the more mutation-prone human metabolic gene. In the presence of nicotinamide adenine dinucleotide phosphate (NADPH), mutant IDH can bind to α-ketoglutaric acid (α-KG) and reduce it to 2-hydroxyglutaric acid (2-HG), participating in various bio...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese General Practice Publishing House Co., Ltd
2024-04-01
|
| Series: | Zhongguo quanke yixue |
| Subjects: | |
| Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/20230284.pdf |
| _version_ | 1797216488943255552 |
|---|---|
| author | ZHAO Jingjing, ZHANG Zhihong, ZHEN Junping |
| author_facet | ZHAO Jingjing, ZHANG Zhihong, ZHEN Junping |
| author_sort | ZHAO Jingjing, ZHANG Zhihong, ZHEN Junping |
| collection | DOAJ |
| description | Isocitrate dehydrogenase (IDH) is the more mutation-prone human metabolic gene. In the presence of nicotinamide adenine dinucleotide phosphate (NADPH), mutant IDH can bind to α-ketoglutaric acid (α-KG) and reduce it to 2-hydroxyglutaric acid (2-HG), participating in various biological processes of tumorigenesis. IDH has been widely studied in glioma and acute myeloid leukemia, and rarely in chondrosarcoma. Chondrosarcoma is prone to recurrence and metastasis due to the presence of high-frequency mutations in the IDH gene, and treatment options are limited after recurrence or metastasis, resulting in a poor prognosis for patients and an urgent clinical need to find new treatment options. This article reviews the role of IDH mutations in the development, prognosis, differential diagnosis and treatment of chondrosarcoma, further elaborates the biological role of IDH gene mutation in the occurrence and development of chondrosarcoma, and provides an outlook on the development of powerful IDH inhibitors and anti-cancer drugs, in order to provide a reference for the establishment of therapeutic regimen and prognostic evaluation. |
| first_indexed | 2024-04-24T11:46:46Z |
| format | Article |
| id | doaj.art-46edc350d451469ab37bb795805aac11 |
| institution | Directory Open Access Journal |
| issn | 1007-9572 |
| language | zho |
| last_indexed | 2024-04-24T11:46:46Z |
| publishDate | 2024-04-01 |
| publisher | Chinese General Practice Publishing House Co., Ltd |
| record_format | Article |
| series | Zhongguo quanke yixue |
| spelling | doaj.art-46edc350d451469ab37bb795805aac112024-04-09T09:20:47ZzhoChinese General Practice Publishing House Co., LtdZhongguo quanke yixue1007-95722024-04-0127111400140410.12114/j.issn.1007-9572.2023.0284Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in ChondrosarcomaZHAO Jingjing, ZHANG Zhihong, ZHEN Junping01. School of Public Health of Shanxi Medical University, Taiyuan 030000, China;2. Department of Imaging, the Second Hospital, Shanxi Medical University, Taiyuan 030000, ChinaIsocitrate dehydrogenase (IDH) is the more mutation-prone human metabolic gene. In the presence of nicotinamide adenine dinucleotide phosphate (NADPH), mutant IDH can bind to α-ketoglutaric acid (α-KG) and reduce it to 2-hydroxyglutaric acid (2-HG), participating in various biological processes of tumorigenesis. IDH has been widely studied in glioma and acute myeloid leukemia, and rarely in chondrosarcoma. Chondrosarcoma is prone to recurrence and metastasis due to the presence of high-frequency mutations in the IDH gene, and treatment options are limited after recurrence or metastasis, resulting in a poor prognosis for patients and an urgent clinical need to find new treatment options. This article reviews the role of IDH mutations in the development, prognosis, differential diagnosis and treatment of chondrosarcoma, further elaborates the biological role of IDH gene mutation in the occurrence and development of chondrosarcoma, and provides an outlook on the development of powerful IDH inhibitors and anti-cancer drugs, in order to provide a reference for the establishment of therapeutic regimen and prognostic evaluation.https://www.chinagp.net/fileup/1007-9572/PDF/20230284.pdfchondrosarcoma|isocitrate dehydrogenase|mutation|tumor treatment|review |
| spellingShingle | ZHAO Jingjing, ZHANG Zhihong, ZHEN Junping Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma Zhongguo quanke yixue chondrosarcoma|isocitrate dehydrogenase|mutation|tumor treatment|review |
| title | Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma |
| title_full | Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma |
| title_fullStr | Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma |
| title_full_unstemmed | Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma |
| title_short | Research Progress and Prospects of Isocitrate Dehydrogenase Gene Mutation in Chondrosarcoma |
| title_sort | research progress and prospects of isocitrate dehydrogenase gene mutation in chondrosarcoma |
| topic | chondrosarcoma|isocitrate dehydrogenase|mutation|tumor treatment|review |
| url | https://www.chinagp.net/fileup/1007-9572/PDF/20230284.pdf |
| work_keys_str_mv | AT zhaojingjingzhangzhihongzhenjunping researchprogressandprospectsofisocitratedehydrogenasegenemutationinchondrosarcoma |